APAF-1 gene, located at chromosome locus 12q23, is a key factor in the mitochondrial apoptotic pathway downstream of p53, and is a potential tumor suppressor gene. We hypothesized that APAF-1 gene dysfunction due to allelic imbalance (AI) contributes to the development and progression of colorectal carcinoma (CRC). AI at APAF-1 locus and microsatellite instability (MIN) in CRCs and adenomas were assessed by multiple microsatellite markers. The frequency of AI significantly increased with tumor progression; 0 of 33 (0%) adenomas, 14 of 49 (29%) primary CRCs, and 18 of 34 (53%) liver metastases had AI. A total of 12 metastases were matched with corresponding primary CRCs; in 11 of 12 (92%) pairs, the metastasis had same AI status as the corresponding primary tumor. APAF-1 mRNA transcription level was significantly decreased with AI in liver metastases (P ¼ 0.009). Promoter hypermethylation was found in three of 35 (9%) primary CRCs and one of 15 (7%) liver metastases by methylation-specific PCR but was not correlated with AI. MIN was observed in 11 of 49 (23%) primary CRCs and was a favorable prognostic factor. Our results suggest that APAF-1 gene haploinsufficiency caused by AI increases with tumor progression, and relates to hepatic metastasis.
Introduction
Sporadic colorectal carcinoma (CRC) arises as a result of a series of somatic mutations, epigenetic inactivation of tumor suppressor genes, and/or activation of oncogenes. Two pathways, the chromosomal instability (CIN) pathway and the microsatellite instability (MIN) pathway, have been proposed and widely accepted (Lengauer et al., 1998) . Loss of heterozygosity (LOH) that causes allelic imbalance (AI) and haploinsufficiency is a hallmark of the CIN pathway, whereas MIN characterizes the MIN pathway. In CRC, previous studies have revealed that accumulations of AI at 8p21-pter, 15q11-q21, 17p12-13, and 18q12-21 (DCC, SMAD2, and DPC4/SMAD4) were strongly associated with the progression of adenoma to carcinoma (Hermsen et al., 2002) . AI of chromosome 18q is an unfavorable prognostic marker in patients with stage II CRC (Jen et al., 1994) and in patients with stage III CRC receiving fluorouracil-based adjuvant chemotherapy (Watanabe et al., 2001) , whereas MIN is reportedly a favorable prognostic indicator in patients with CRC (Gryfe et al., 2000; Hemminki et al., 2000) .
Epigenetic inactivation by hypermethylation of promoter regions of tumor suppressor genes such as p16, APC, VHL, and hMLH1 has been found in CRCs Deng et al., 1999; Jones, 1999; Esteller et al., 2000; Robertson and Jones, 2000; Xiong et al., 2001; Herman, 2002) . Methylation of cytosines in CpG islands in the promoter region affects promoter activity and can downregulate gene transcription (Jones, 1999) . Because the promoter hypermethylation of genes in carcinoma cells is as significant as deletions or mutations (Jones, 1996; Esteller and Herman, 2002; Herman and Baylin, 2003) , hypermethylation of key regulatory genes can play a significant role in transformation of colon epithelium as well as tumor progression.
APAF-1, a key factor in the mitochondrial apoptotic pathway downstream of p53 (Robles et al., 2001) , is associated with resistance to apoptosis. Activated p53 is a transcriptional transactivator of genes that controls the release of cytochrome c from mitochondria during apoptosis (Fortin et al., 2001; Moroni et al., 2001; Robles et al., 2001; Mihara et al., 2003) . In the presence of cytochrome c, APAF-1 can bind to procaspase 9 and form an apoptosome. Activation of caspase 9 in the apoptosome results in activation of downstream caspases such as 3, 6, and 7 (Li et al., 1997) . Consequently, the loss of APAF-1 gene function leads to defects in the execution of apoptotic programmed cell death and may account for cellular resistance to chemo-, radio-, and immunotherapy. APAF-1 is located at chromosome loci 12q23 , and frequent AI in the 12q22-23 region has been reported in melanomas (Soengas et al., 2001; Fujimoto et al., 2004) , male germ cell tumors (Murty et al., 1996) , and pancreatic (Kimura et al., 1998; Yatsuoka et al., 2000) , ovarian (Hatta et al., 1997) and gastric carcinomas (Schneider et al., 2003) . In melanomas, AI is associated with a reduction of APAF-1 mRNA expression levels (Soengas et al., 2001; Fujimoto et al., 2004) , and AI in the 12q22-23 region is related to poor prognosis of patients with American Joint Committee on Cancer (AJCC) stage III/IV melanoma . However, the role of APAF-1 in CRC has not been studied.
Because p53 gene alteration is common and its function is impaired in most advanced CRCs, the p53 pathway involving APAF-1 should be a key route activating apoptosis. We hypothesized that APAF-1 gene dysfunction contributes to the development and progression of CRC. To examine the role of APAF-1 loss in the tumorigenesis of CRCs, we assessed AI on the APAF-1 locus of colorectal adenomas, primary CRCs, and liver metastatic lesions. We also assessed epigenetic inactivation of APAF-1 by promoter hypermethylation to determine gene transcription silencing. In addition, MIN was determined by the analysis of the PCR products of the microsatellite markers to study the involvement of MIN pathway and its relation with the CIN pathway represented by AI of the APAF-1 locus.
Results

AI at APAF-1 locus
To assess the AI status, seven microsatellite markers encompassing the APAF-1 gene as shown in Figure 1 were assessed for all adenomas, primary CRCs, and liver metastases. AI was indeterminable (noninformative in all microsatellite markers) in three of 119 tumors. One was a liver metastasis showing homozygosity in all microsatellite markers; the other two were liver metastases showing MIN in all heterozygous microsatellite markers. Representative capillary array electrophoresis (CAE) results demonstrating AI in tumors are shown in Figure 2a . In the remaining 116 specimens, which have at least one informative microsatellite marker, none of 33 (0%) adenomas, 14 of 49 (29%) primary CRCs, and 18 of 34 (53%) liver metastases had AI at APAF-1 locus (Figure 3 ). The frequency of AI increased significantly as the tumor progressed from adenoma to primary CRC and then to metastasis. The AI frequency was significantly higher in primary CRCs than in adenomas (P ¼ 0.0005, Fisher's exact test), and was significantly higher in liver metastases than in primary CRCs (P ¼ 0.038, Fisher's exact test). AI at APAF-1 locus in liver metastases did not correlate with the size or number of metastasis in the liver (data not shown). Among the seven microsatellite markers, D12S296 was closest to the APAF-1 gene (65 kb centromeric) and had the highest AI frequency (38%) in primary CRC specimens. As shown in Table 1 , no relation was found between AI status and other clinicopathological characteristics (sex, age, tumor site, AJCC TNM scores and stage, histopathological grade, and tumor diameter) in primary CRCs. Among 49 patients with primary CRCs, no correlation with AI status and survival was found by univariate Cox's proportional hazard model (Table 2) .
Methylation status of APAF-1 promoter region
Methylation status of APAF-1 promoter region was assessed in 35 primary CRCs (seven AI ( þ ) and 28 AI (À) tumors) and 15 liver metastases (six AI ( þ ) and nine AI (À) tumors). Methylation status was determined by methylated-specific and unmethylated-specific peaks by methylation-specific PCR (MSP) (Figure 4 ). DNA from normal peripheral blood lymphocytes (PBLs) showed only an unmethylated-specific peak (Figure 4a ), whereas SssI methylase-treated (forced hypermethylation) DNA showed only a methylated-specific peak (Figure 4b ). Hypermethylation was found in three of 35 (9%) primary CRCs and one of 15 (7%) liver metastases by MSP. There was no correlation between methylation status and AI status at APAF-1 locus. All AI ( þ ) specimens were unmethylated. To evaluate the effect of AI on mRNA transcription level, we assessed the mRNA level of representative liver metastatic specimens with known AI status. Tumor mRNA was extracted from precisely dissected tumor cells using the PixCell II Laser Capture Microdissection (LCM) System (Arcturus Engineering, Mountain View, CA, USA), avoiding contamination of nontumor cells. Absolute copy numbers of APAF-1 and GAPDH in 250 ng of total RNA were quantified by quantitative real-time reverse-transcriptase PCR (qRT-PCR). To minimize the influence of formalin fixation and degradation of the mRNA, the relative copy number of APAF-1 against the GAPDH house-keeping gene was used instead of the absolute copy number of APAF-1. Relative copy numbers of APAF-1 of the five AI ( þ ) liver metastases and five AI (À) liver metastases were 5.971.1 Â 10 À2 and 10.770.9 Â 10 À2 (mean7s.e.m.), respectively. The transcription level of mRNA was significantly lower in AI ( þ ) tumors than in AI (À) tumors (P ¼ 0.009, Wilcoxon's rank-sum test) ( Figure 5 ). The average mRNA transcription level of AI (À) tumors was approximately twice that of AI ( þ ) tumors, and it was consistent with the expected haploinsufficiency caused by the AI of the tumors.
Concordance of AI between a liver metastasis and its primary CRC
A total of 12 liver metastases [three AI (À) and nine AI ( þ )] were matched with their primary CRCs to study the concordance of AI status in the development of liver metastasis. The metastasis and its primary CRC had the same AI status in 11 of 12 (92%) pairs: three AI (À) and eight AI ( þ ). In the remaining pair, the primary CRC was AI (À) but the metastasis was AI ( þ ).
Microsatellite instability
MIN was determined by the analysis of PCR products of the AI study. Representative CAE result demonstrating MIN in a tumor is shown in Figure 2b . Three of 33 (9%) adenomas, 11 of 49 (23%) primary CRCs, and seven of 37 (19%) liver metastases showed MIN in one or more microsatellite marker analyses. There was no correlation between MIN status and AI status of APAF-1 locus. Among the 49 patients with primary CRCs, those with MIN ( þ ) primary CRC had significantly better prognosis by univariate Cox's proportional hazard model (P ¼ 0.003) ( Table 2) and by multivariate Cox's proportional hazard model (P ¼ 0.0001) with covariates of AJCC T, N, and M scores and histopathological grade (Table 3) .
Discussion
In the model of genetic alteration in colorectal carcinogenesis (Vogelstein et al., 1988) , K-ras mutation and AI at the APC gene locus are early genetic changes that occur in adenomas, whereas AI of 18q (DCC, SMAD2, and DPC4/SMAD4) and 17q (p53) are late significant events. Invasive cancer cells require a mechanism for avoiding apoptosis to survive. Inactivation of p53 gene, which is a component of an apoptotic pathway, is common in most advanced CRCs, but infrequent in colorectal adenomas (Hao et al., 2002) . Therefore, it is suggested that the p53 apoptotic pathway is inactivated when tumor cells transform from adenoma into carcinoma. Considering that APAF-1 gene is a key factor in the mitochondrial apoptotic pathway downstream of p53 (Robles et al., 2001) and necessary for the later activation phase of apoptosis, inactivation of APAF-1 gene may also be important for colorectal carcinogenesis. Tumor cells with APAF-1 downregulation are expected to be advantageous for survival by escaping from extracellular apoptotic signals such as tumor necrosis factor (TNF) and TNF-related apoptosis-inducing ligand (TRAIL). Therefore, we hypothesized that APAF-1 inactivation or downregulation caused by AI at APAF-1 locus might affect tumor cell resistance from apoptotic signals and thereby facilitate progression of CRC. To know the frequency of occurrence of AI at APAF-1 locus in the carcinogenic pathway, we studied AI in adenoma, primary CRC, and liver metastasis, representing each progressive stage of colorectal carcinogenesis. In this study, AI at APAF-1 locus was found in primary or metastatic CRCs but not in adenomas. Therefore, this genetic alteration may potentially be important in CRC development, like the other genetic alterations found in the later stage of colorectal carcinogenesis, such as p53 gene inactivation or deletion of 18q. In addition, the significantly higher frequency of AI in liver metastases than in primary CRCs suggests that AI at APAF-1 gene locus may facilitate liver metastasis. The high frequency of AI at APAF-1 locus in liver metastases supports a correlation between the ability of cancer cells to escape apoptotic signals and its likelihood of metastasizing to distant sites such as the liver. Therefore, AI of APAF-1 gene expression might be expected to have an adverse effect on prognosis. However, despite a trend for better prognosis in patients with AI (À) primary tumors, there was no significant correlation between AI status of primary CRC and overall survival. This may be due to effective therapeutic interventions. Further investigation with a larger series of patients from randomized controlled study will be required to determine the prognostic significance of AI at APAF-1 in primary CRC.
In this study, there was no significant correlation between AI at APAF-1 locus in primary CRC and AJCC N and M scores. However, the frequency of AI in the liver metastases was higher than that in the primary CRCs. We speculate that cancer cells in a primary lesion transformed to AI ( þ ) at APAF-1 locus obtain potential of escaping from apoptosis. This event combined with metastasis to the liver allows a greater probability of survival of the spreading cancer cells at a distant site. The reason as to why the frequencies of AI ( þ ) in M1 and N1 or N2 tumors are not significantly higher may be related to the heterogeneity of the tumor cells in the primary CRCs. In general, detection of AI ( þ ) cells using microsatellite markers can be easily affected by the contamination of AI (À) cells. Tumors having o50% AI ( þ ) cancer cells would be determined as AI (À) with our definition. Therefore, the tumors harboring AI ( þ ) cells in part, which would have been determined as AI (À) in our study, could have metastatic potential.
In the concordance analysis with 12 pairs of primary CRCs and liver metastases, there was only one pair in which AI status changed (the primary lesion was AI (À) but the metastasis was AI ( þ )), while the other pairs maintained AI status during the development of metastasis. Because apoptosis-resistant clones are more APAF-1 allelic imbalance in colorectal carcinoma N Umetani et al likely to survive during the process of metastasis to the liver, clones with haploinsufficiency of APAF-1 caused by AI should become dominant in the metastatic lesions. AI ( þ ) primary CRCs were suggested to have higher ability to metastasize than AI (À) primary CRCs The relations between AI at APAF-1 locus and mRNA transcription level in liver metastases were assessed to ascertain the correlation between AI status and mRNA expression level of APAF-1 gene. Because liver metastases have fewer nontumor cells such as stromal cells compared to primary CRCs, they are more suitable for mRNA expression study, which is sensitive to contamination by nontumor cells. qRT-PCR results revealed that AI ( þ ) tumors had significantly lower expression level of mRNA than AI (À) tumors, in accordance with the results of our previous study in melanoma . The relative mRNA level was reduced to 45% in AI ( þ ) tumors; this reduction can be explained as a haploinsufficiency caused by deletion of one allele. Extracellular apoptotic signals on tumor cells may induce expression of APAF-1 gene, but the transcription rate would be limited by the reduction of the allele number.
Methylation status of APAF-1 gene was also studied. Hypermethylation of promoter region of a gene is an important mechanism of epigenetic gene silencing. Because many tumor-related genes have been reported to be inactivated by promoter hypermethylation along with AI, we assessed the methylation status of APAF-1 promoter region. Hypermethylation of APAF-1 occurred in low frequency and was absent in AI ( þ ) tumors. This suggests that hypermethylation is not a major factor silencing APAF-1 expression in CRC.
After the initial publication of AI at APAF-1 gene in melanomas by Soengas et al. (2001) , the APAF-1 gene locus was reassessed. The current information in the National Center for Biotechnology Information (NCBI) database indicates that the APAF-1 gene is located more distal (40.3 Mb) from the chromosome 12q centromere, and this location change may significantly affect the result of AI study. Therefore, we studied AI status by seven microsatellite markers that encompassed not only the current APAF-1 locus between D12S296 and D12S346 but also the locus between D12S1657 and D12S393, which previously had been considered the locus of APAF-1. In the present study, the frequency of AI between D12S1657 and D12S393 would be evaluated as 0-6, 18-31, and 56-62% in adenomas, primary CRCs, and liver metastases, respectively. The high frequency of AI at this locus in liver metastases suggests the presence of other tumor suppressor genes or tumorrelated genes near the microsatellite markers D12S1657 and D12S393. Currently, there is no known or definite candidate tumor suppressor gene identified in the vicinity of this locus.
The MIN pathway is as important as the CIN pathway in colorectal carcinogenesis (Lengauer et al., 1998) , and MIN status can be evaluated by using microsatellite markers located throughout the genome. We evaluated the MIN status from the CAE results of microsatellite markers used for APAF-1 gene AI study. MIN has been reported in approximately 13-16% of sporadic CRCs and in virtually all CRCs arising in patients with hereditary nonpolyposis colorectal cancer (HNPCC) (Aaltonen et al., 1993; Thibodeau et al., 1993; Herman et al., 1998) . In this study, we found a similar frequency of MIN ( þ ) CRCs, and MIN was independent of AI at APAF-1. Consistent with the previous report that associated MIN ( þ ) phenotype with favorable prognosis (Gryfe et al., 2000; Hemminki et al., 2000) , our results showed that patients with MIN ( þ ) primary CRCs had favorable prognosis by univariate and multivariate survival analyses and that MIN status of primary CRC was an independent prognostic factor.
In conclusion, AI of APAF-1 locus at 12q23 was not found in colorectal adenomas but was frequent in primary CRCs and liver metastases of CRC. The frequency of AI was significantly higher in liver metastases, and expression level of APAF-1 mRNA was correlated with AI status. The haploinsufficiency caused by AI of APAF-1 gene may favor the development of clinically significant CRC metastases.
Materials and methods
Tissue samples and clinicopathological information
We analysed AI status of 119 neoplastic colorectal tumors (33 adenomas, 49 primary CRCs, and 37 liver metastases) from 89 patients selected by the database coordinator based on those patients who underwent colectomy, proctectomy, or endoscopic treatment between 1995 and 2001 at Saint John's Health Center, Santa Monica. The primary CRCs were collected from AJCC stage I-IV carcinomas. The liver metastases were surgically resected synchronous or metachronous metastases of CRC. For APAF-1 mRNA expression analysis, 10 specimens of liver metastases were studied. All specimens were formalin-fixed, paraffin-embedded archival tissues (PEAT) obtained from the pathology department. Tumor tissues were reviewed by the pathologist to confirm histopathologic status. All patients in this study consented and the study was according to the guidelines set forth by JWCI Institutional Review Board (IRB) committee. Tumors were classified and staged according to the revised guidelines set by the AJCC. Clinicopathological data from the tumor registry were obtained after IRB approval for all patients. To study the concordance of AI status during development of liver metastasis, AI status was assessed in 12 liver metastases and their corresponding primary CRCs.
DNA extraction and sodium bisulfite modification of DNA Several 5-mm sections were cut with a microtome from PEAT under sterile conditions as previously described (Shinozaki et al., 2004) . One section for each tumor was stained with hematoxylin after deparaffinization and the neoplastic lesions were precisely dissected using LCM as previously described (Hoon et al., 2002) . Dissected tissues were digested with 50 ml of proteinase K containing lysis buffer at 501C for 5 h, followed by heat deactivation of proteinase K at 951C for 10 min. Lysate was directly used as a template for PCR as previously described (Nakayama et al., 2001; Hoon et al., 2002) . Control (non-neoplastic) DNA for each tumor was obtained from its tumor-adjacent normal tissue, that is, normal mucosa for primary CRCs or adenomas, and normal liver tissue for liver metastases of same sections of the tumors. Sodium bisulfite modification was applied on extracted genomic DNA of tissue specimens for MSP as previously described (Spugnardi et al., 2003) .
Microsatellite analysis
AI was assessed by seven microsatellite markers (D12S1657, D12S393, D12S1063, D12S1706, D12S296, D12S346, and D12S1059) encompassing the APAF-1 gene locus at 12q23 (Figure 1) 0 -CCAGCTTACCAACTGCAGAT-3 0 . Forward primers were labeled with WellRED dye-labeled phosphoramidites (Beckman Coulter Inc., Fullerton, CA, USA). The PCR amplification was performed in a 10-ml reaction volume with 1 ml template for 40 cycles of 30 s at 941C, 30 s at 551C, and 30 s at 721C, followed by a 7-min final extension at 721C. PCR product separation was performed using CAE by CEQ 8000XL (Beckman Coulter Inc.). Peak fluorescent intensity indicating the amount of PCR amplicon and the PCR amplicon size were calculated by software for fragment analysis system (Beckman Coulter Inc.). For each microsatellite marker, 50% or more reduction of fluorescent intensity of one allele for tumor DNA as compared to the corresponding control DNA was defined as AI (Figure 2a) . The CAE result at each microsatellite marker showing homozygosity in control DNA or MIN in tumor DNA was defined as noninformative. The AI status of the APAF-1 gene locus of the tumors was determined according to the nearest informative marker. Specimens with no informative markers were indeterminable of AI status and were excluded from AI analysis. MIN was determined by the change of repeating motifs in the microsatellite markers within the tumor when compared to normal tissue as defined previously (Boland et al., 1998) . Tumors having instability in one or more microsatellite markers were defined as MIN ( þ ), and tumors stable in all microsatellite markers were defined as MIN (À). A representative CAE result demonstrating MIN in a tumor is shown in Figure 2b .
RNA extraction and analysis of mRNA expression level
For mRNA expression analysis, total RNA was extracted from 10 specimens of metastases. A total of 1-3 5-mm sections of each specimen were stained with methyl green after deparaffinization, and the tumor cells were precisely microdissected using LCM following the manufacturer's protocol of the Paraffin Block RNA Isolation Kit (Ambion, Austin, TX, USA) with modifications . Quality and quantity of extracted total RNA were measured by UV absorption spectrophotometry to ensure that it was suitable for the assay.
After extraction of total RNA, reverse-transcriptase reactions were performed on 1.0 mg of total RNA using Moloney murine leukemia virus reverse-transcriptase (Promega, Madison, WI, USA) with the mixture of oligo-dT and random hexamers as the primers, as previously described . qRT-PCR assay was performed on the iCycler iQ Real-Time thermocycler detection system (Bio-Rad Laboratories, Hercules, CA, USA) . For each PCR, the reaction mixture consisted of cDNA template synthesized from 250 ng of total RNA, 1 mM of forward primer (5 0 -ACATTTCTCACGATGCTACC-3 0 ) and reverse primer (5 0 -CAATTCATGAAGTGGCAA-3 0 ), and 0.3 mM of fluorescence resonance energy transfer probe (5 0 -FAM-TGCTGA-CAAGACTGCAAAGATCTG-BHQ-1-3 0 ). PCR amplification was performed in a 20-ml reaction volume for 45 cycles of 60 s at 941C, 60 s at 551C, and 60 s at 721C. The standard curve was established for quantifying mRNA copy numbers by using nine known copy numbers of serially diluted (10 8 -10 0 copies) plasmids containing APAF-1 cDNA sequence. Reaction without templates was performed as a negative control in each study. PCR products were electrophoresed on 2% agarose gels to confirm correct product size and absence of nonspecific bands. The mRNA expression level of the housekeeping gene GAPDH was measured by qRT-PCR as an internal reference with a standard curve to determine the integrity and quality of template RNA for all specimens. The ratio of APAF-1 and GAPDH expression level was calculated as (absolute copy number of APAF-1)/(absolute copy number of GAPDH) as previously described .
Detection of promoter hypermethylation
The methylation status of APAF-1 promoter region was assessed in a subset of specimens from primary tumors and hepatic metastases. The assay involved sodium bisulfite modification followed by MSP to determine the methylation status as previously described (Spugnardi et al., 2003) . SssI methylase-treated and -untreated normal DNA obtained from PBL of a healthy donor was used as a positive and a negative control, respectively (Renbaum et al., 1990) . Primers used for MSP were as follows: methylated-specific forward, 5 0 -GTCGTTGTTCGAGTTCGGTA-3 0 ; reverse, 5 0 -GCGTAA-AAATACCCGCCTAC-3 0 ; unmethylated-specific forward, 5 0 -GGGTGTGTTGTTGTTGTTTGA-3 0 ; reverse, 5 0 -AAATAC-CCACCTACCCCACA-3 0 . Each forward primer contained three CpG sites and each reverse primer contained two CpG sites within the annealing sequence. Forward primers were labeled with WellRED dye-labeled phosphoramidites (Beckman Coulter Inc.). The PCR amplification was performed in a 10-ml reaction volume with 1 ml template for 40 cycles of 30 s at APAF-1 allelic imbalance in colorectal carcinoma N Umetani et al 941C, 30 s at 551C, and 30 s at 721C, followed by a 7-min final extension at 721C. Detection of PCR products was analysed by CAE using CEQ 8000XL (Beckman Coulter Inc.).
Statistical analysis
The relation between APAF-1 AI status and tumor classification (adenomas, primary CRCs, liver metastases) was assessed using Fisher's exact test. The relation between APAF-1 AI status and other clinicopathological or genetic characteristics was assessed using Fisher's exact test, w 2 test, or Wilcoxon's rank-sum test. For survival analysis, Cox's proportional hazard model was used for univariate and multivariate analyses of clinicopathological or genetic characteristics. Variables suggested by the univariate analyses (Po0.10) were entered into the multivariate analysis. For comparison of mRNA expression level, Wilcoxon's rank-sum test was used. The statistical package SAS JMP ver. 5.0.1 (SAS Institute Inc., Cary, NC, USA) was used to conduct statistical analyses. A Pvalue o0.05 (two-tailed) was considered as significant.
